Target- |
Mechanism- |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase 2, Open-Label, Randomized, Parallel Group, Placebo-Controlled, Single-Center Study to Assess Anti-microbial Efficacy and Safety of DCN01 Compared to Unisol® Following Topical Periocular Administration in Healthy Volunteers
This proof-of-concept study evaluates the clinical efficacy and safety of DCN01 in prepping of the periocular region.
100 Clinical Results associated with Deacon Biosciences, Inc.
0 Patents (Medical) associated with Deacon Biosciences, Inc.
100 Deals associated with Deacon Biosciences, Inc.
100 Translational Medicine associated with Deacon Biosciences, Inc.